NCT06206824View on ClinicalTrials.gov

Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Healthy VolunteersDown SyndromeAlzheimer's Disease
Interventions
DRUG

Leucettinib-21

See arm's description.

Trial Locations (1)

38610

RECRUITING

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
collaborator

France 2030 program

UNKNOWN

collaborator

European Innovation Council

OTHER

collaborator

Fondation Jérôme Lejeune

OTHER

lead

Perha Pharmaceuticals

INDUSTRY

NCT06206824 - Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease | Biotech Hunter | Biotech Hunter